DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7f6f40/parkinsons_diseas) has announced the addition of Global Markets Direct's new report "Parkinson's Disease - Pipeline Review, Q1 2011" to their offering.
Global Markets Directs, 'Parkinson's Disease - Pipeline Review, Q1 2011', provides an overview of the Parkinson's Disease therapeutic pipeline. This report provides information on the therapeutic development for Parkinson's Disease , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease . 'Parkinson's Disease - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.
Scope
- A snapshot of the global therapeutic scenario for Parkinson's Disease .
- A review of the Parkinson's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Parkinson's Disease pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Parkinson's Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Key Topics Covered:
- Summary
- Introduction
- Comparative Analysis
- Comparative Analysis
- Late Stage Drug Profiles Companies
- Parkinson's Disease - Featured News
- Appendix
Drug Profiles
- Apomorphine - Drug Profile
- Caffeine - Drug Profile
- Clarithromycin + Amoxicillin + Omeprazole - Drug Profile
- Coenzyme Q10 - Drug Profile
- Coenzyme Q10 + Vitamin E - Drug Profile
- Deferiprone - Drug Profile
- Donepezil - Drug Profile
- Duodopa - Drug Profile
- Exelon - Drug Profile
- Florbetapir F 18 - Drug Profile
- IPX066 - Drug Profile
- KW-6002 - Drug Profile
- KW-6500 - Drug Profile
- Lisuride TDS - Parkinson - Drug Profile
- Paroxetine + Venlafaxine - Drug Profile
- Pimavanserin tartrate - Drug Profile
- Preladenant - Drug Profile
- Propofol - Drug Profile
- Safinamide - Drug Profile
- Stalevo - Drug Profile
- Traditional Chinese Medicinal Mixture - Drug Profile
- venlafaxine - Drug Profile
Companies Mentioned:
- Bristol-Myers Squibb Company
- Genzyme Corporation
- Kyowa Hakko Kirin Co., Ltd.
- Abbott Laboratories
- Biogen Idec Inc.
- NsGene A/S
- Valeant Pharmaceuticals International
- AstraZeneca PLC
- Eli Lilly and Company
- Tekmira Pharmaceuticals Corp.
- Endo Pharmaceuticals Holdings Inc.
- Merck & Co., Inc.
- Amarin Corporation plc
- Amicus Therapeutics, Inc.
- Ligand Pharmaceuticals Incorporated
- ReGenX Biosciences, LLC
- Neuren Pharmaceuticals Limited
- Neurologix, Inc.
- NeuroSearch A/S
- Cortex Pharmaceuticals, Inc.
- ACADIA Pharmaceuticals Inc.
- Alnylam Pharmaceuticals, Inc
- ProteoTech, Inc.
- Heptares Therapeutics Ltd.
- Neuraltus Pharmaceuticals, Inc.
- ArmaGen Technologies, Inc.
- Varinel, Inc.
- PharmaNeuroBoost N.V.
- UNeMed
- Ampio Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/7f6f40/parkinsons_diseas